Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
ActiveMax® Recombinant Human VEGF165 (HPLC-verified), 50µg  

ActiveMax® Recombinant Human VEGF165 (HPLC-verified), 50µg

ActiveMax® Recombinant Human VEGF165 (ActiveMax® Human VEGF165) Ala 27 - Arg 191 was produced in human 293 cells (HEK293)

Synonyms: Vascular endothelial growth factor A-165, VEGF-A165 cytokine, Vascular permeability factor, VPF-165

More details

VE5-H4210-050

Availability: within 7 days

402,00 €

Background: VEGF165 is the most abundant splice variant of VEGF-A [1,2]. VEGF165 is produced by a number of cells including endothelial cells, macrophages and T cells. VEGF165 is involved in angiogenesis, vascular endothelial cell survival, growth, migration and vascular permeability [1]. VEGF gene expression is induced by hypoxia, inflammatory cytokines and oncogenes [1,2]. VEGF165 binds to heparan sulfate and is retained on the cell surface and in the extracellular matrix [2,3]. VEGF165 binds to the receptor tyrosine kinases, VEGFR1 and VEGFR2 [1]. VEGF165 is the only splice variant that binds to co-receptors NRP-1 and NRP-2 [1-3] that function to enhance VEGFR2 signaling [1]. Binding of VEGF165 to VEGFR1 and VEGFR2 leads to activation of the PI3K/AKT, p38 MAPK, FAK and paxillin [1]. VEGF plays a key role in tumor angiogenesis in many cancers [2].

Source
ActiveMax® Recombinant Human VEGF165 (ActiveMax® Human VEGF165) Ala 27 - Arg 191 (Accession # NP_001165097) was produced in human 293 cells (HEK293)

Molecular Characterization
ActiveMax® Human VEGF165 contains no "tag", and has a calculated MW of 19 kDa (monomer). The predicted N-terminus is Ala 27. As a result of glycosylation, the reducing (R) protein migrates as 24 kDa (monomer), and the non-reducing (NR) protein migrates as 43-50 kDa (homodimer) in SDS-PAGE .

Endotoxin
Less than 1.0 EU per μg of the ActiveMax® Human VEGF165 by the LAL method.

Purity
>98% as determined by SDS-PAGE.
>95% as determined by SEC-HPLC.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally Trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
Avoid repeated freeze-thaw cycles. No activity loss was observed after storage at:
In lyophilized state for 1 year (4°C-8°C); After reconstitution under sterile conditions for 1 month (4°C-8°C) or 3 months (-20°C to -70°C).

Bioactivity
Measured by its binding ability in a functional ELISA. Immobilized Human VEGF165, Tag Free (Catalog # VE5-H4210) at 0.01 μg/mL (100 μL/well) can bind Human VEGF R1, His Tag (Catalog # VE1-H5220) with a linear range of 4-31 ng/mL (QC tested). Measured by its binding ability in a functional ELISA. Immobilized Human VEGF165, Tag Free (Catalog # VE5-H4210) at 0.01 μg/mL (100 μL/well) can bind VEGFR1/R2-Fc with a linear range of 0.4-6 ng/mL (Routinely tested). Measured by its ability to bind Human VEGF R1, His Tag (Cat# VE1-H5220) in the SPR assay (Biacore 2000) with an estimated KD of 0.1nM (Routinely tested).Measured by its ability to bind Human VEGF R2, His Tag (Cat# KDR-H5227) in the SPR assay (Biacore 2000) with an estimated KD < 50nM (Routinely tested).

References

(1)Takahashi, H. and Shibuya, M., 2005, Clin Sci (Lond) 109, 227-41.
(2)Neufeld, G. et al., 1999, FASEB J 13, 9-22.
(3)Robinson, C.J. and Stringer, S.E., 2001, J Cell Sci 114, 853-65.

The following products could also be interesting for you: